Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 Meeting Abstract
| Authors: | Li, B. T.; Planchard, D.; Goto, K.; Smit, E. F.; De Langen, J.; Goto, Y.; Ninomiya, K.; Kubo, T.; Pérol, M.; Felip, E.; Hayashi, H.; Nakagawa, K.; Shimizu, J.; Nagasaka, M.; Pereira, K. M. C.; Taguchi, A.; Ali, A.; Karnoub, M.; Yonemochi, R.; Jänne, P. A. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S762 |
| End Page: | S763 |
| Language: | English |
| ACCESSION: | WOS:001087480201645 |
| DOI: | 10.1016/j.annonc.2023.09.2354 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1321MO -- Source: Wos |
